Tandem Diabetes Care Appoints Dr. Kathleen McGroddy-Goetz to Board of Directors
June 04 2020 - 9:15AM
Business Wire
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin
delivery and diabetes technology company, today announced the
appointment of Kathleen McGroddy-Goetz, Ph.D., as an independent
member of its Board of Directors effective June 8, 2020. Dr.
McGroddy-Goetz has extensive experience commercializing pioneering
technologies spanning from microelectronics through cloud, advanced
data analytics, AI, hardware, software, and middleware with an
emphasis on healthcare and life sciences applications.
“We welcome Kathy to our Board of Directors at this important
next stage in Tandem’s evolution,” said John Sheridan, president
and CEO, Tandem Diabetes Care. “She is a leader in creating
transformative healthcare and life sciences solutions, which brings
tremendous value to our Company as we advance our mission to
improve the lives of people with diabetes.”
Dr. McGroddy-Goetz has more than 25 years of experience leading
global teams across business development, strategy, research and
development, and product management.
She is currently the Global Head of Strategic Partnerships at
Medidata Solutions, a Dassault Systemès Company, and VP of
Strategy, Partnerships and Alliances at Medidata’s Acorn AI
subsidiary.
Prior to her current positions, Dr. McGroddy-Goetz was Vice
President of Global Strategic Partnerships and Solutions at IBM,
where she played a critical role in creating and launching Watson
Health. Dr. McGroddy-Goetz received a B.S. in Physics from SUNY
Binghamton and a Ph.D. in Molecular Biophysics from Cornell
University.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical
device company dedicated to improving the lives of people with
diabetes through relentless innovation and revolutionary customer
experience. The Company takes an innovative, user-centric approach
to the design, development and commercialization of products for
people with diabetes who use insulin. Tandem’s flagship product,
the t:slim X2™ insulin pump, is capable of remote software updates
using a personal computer and features integrated continuous
glucose monitoring. Tandem is based in San Diego, California.
Tandem Diabetes Care is a registered trademark and t:slim X2 is
a trademark of Tandem Diabetes Care, Inc.
Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use
#tslimX2, and $TNDM. Follow Tandem Diabetes Care on Facebook at
www.facebook.com/TandemDiabetes. Follow Tandem Diabetes Care on
LinkedIn at https://www.linkedin.com/company/tandemdiabetes.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200604005216/en/
Media Contact: Steve Sabicer 714-907-6264
ssabicer@thesabicergroup.com
Investor Contact: Susan Morrison 858-366-6900 x7005
IR@tandemdiabetes.com
Tandem Diabetes Care (NASDAQ:TNDM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tandem Diabetes Care (NASDAQ:TNDM)
Historical Stock Chart
From Sep 2023 to Sep 2024